Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O95235

UPID:
KI20A_HUMAN

ALTERNATIVE NAMES:
GG10_2; Mitotic kinesin-like protein 2; Rab6-interacting kinesin-like protein; Rabkinesin-6

ALTERNATIVE UPACC:
O95235; B4DL79; D3DQB6

BACKGROUND:
The Kinesin-like protein KIF20A, known by alternative names such as GG10_2 and Rabkinesin-6, is crucial for cytokinesis during mitosis. It ensures the proper function of the chromosome passenger complex (CPC) and the recruitment of PLK1 to the central spindle. Its interaction with RAB6A and RAB6B and its role in the transport of Golgi membranes highlight its significance in cellular transport mechanisms.

THERAPEUTIC SIGNIFICANCE:
Given KIF20A's critical function in familial restrictive cardiomyopathy 6, a severe heart condition with prenatal onset, it represents a promising target for drug discovery. Exploring KIF20A's mechanisms offers a pathway to innovative treatments for heart failure.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.